Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Budesonide + carmoterol is a fixed-dose combination inhaler under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Budesonide is an inhaled corticosteroid that reduces inflammation in the airways, while carmoterol is a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle to improve airflow. The combination aims to provide both anti-inflammatory and bronchodilatory effects for maintenance therapy in patients with obstructive airway diseases. Carmoterol, unlike formoterol or salmeterol, is an ultra-long-acting LABA designed for once-daily dosing. This combination has been investigated as a potential alternative to other ICS/LABA combinations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on budesonide + carmoterol.